Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 Sep;16(3):353–361. doi: 10.1128/aac.16.3.353

Correlation of aminoglycoside dosages with serum concentrations during therapy of serious gram-negative bacillary disease.

M T Reymann, J A Bradac, C G Cobbs, W E Dismukes
PMCID: PMC352860  PMID: 507790

Abstract

We prospectively evaluated serum aminoglycoside (AMG) concentrations in 120 patients who received gentamicin or tobramycin for serious gram-negative bacillary disease. AMG serum concentrations were assayed by microbiological and radioimmunoassay techniques. Correlation between the two assay methods was good. When AMG doses were based on total body weight, there was no significant correlation between AMG dosage administered and serum concentrations in patients with either normal or abnormal renal function. The use of ideal body weight for calculation of AMG dosage improved this correlation significantly except in hemodialysis patients. AMG-induced nephrotoxicity occurred in 13 patients. No significant association was noted between the occurrence of toxicity and the specific AMG given or with other commonly recognized risk factors. Among study groups, peak AMG serum concentrations failed to exceed the minimal inhibitory concentration of the infecting organism in 17 to 33% of the cases. Serum inhibitory levels of greater than or equal to 1:8 were not associated with improved survival. There was no significant difference in mortality between the gentamicin- and tobramycin-treated groups. We advise base-line serum AMG levels in seriously ill patients with gram-negative bacillary disease and additional bacteriological studies in selected situations.

Full text

PDF
353

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M., Brown R. B., Shen D., Gibaldi M., Weinstein L. Predictability of blood levels of gentamicin in man. J Infect Dis. 1975 Aug;132(2):165–174. doi: 10.1093/infdis/132.2.165. [DOI] [PubMed] [Google Scholar]
  2. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  3. Bennet W. M., Gilbert D. N., Houghton D., Porter G. A. Gentamicin nephrotoxicity--morphologic and pharmacologic features. West J Med. 1977 Jan;126(1):65–68. [PMC free article] [PubMed] [Google Scholar]
  4. Bennett W. M., Hartnett M. N., Gilbert D., Houghton D., Porter G. A. Effect of sodium intake on gentamicin nephrotoxicity in the rat. Proc Soc Exp Biol Med. 1976 Apr;151(4):736–738. doi: 10.3181/00379727-151-39296. [DOI] [PubMed] [Google Scholar]
  5. Chan R. A., Benner E. J., Hoeprich P. D. Gentamicin therapy in renal failure: a nomogram for dosage. Ann Intern Med. 1972 May;76(5):773–778. doi: 10.7326/0003-4819-76-5-773. [DOI] [PubMed] [Google Scholar]
  6. Cutler R. E., Gyselynck A. M., Fleet W. P., Forrey A. W. Correlation of serum creatinine concentration and gentamicin half-life. JAMA. 1972 Feb 21;219(8):1037–1041. [PubMed] [Google Scholar]
  7. Dahlgren J. G., Anderson E. T., Hewitt W. L. Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother. 1975 Jul;8(1):58–62. doi: 10.1128/aac.8.1.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dobbs S. M., Mawer G. E. Intravenous injection of gentamicin and tobramycin without impairment of hearing. J Infect Dis. 1976 Aug;134 (Suppl):S114–S117. doi: 10.1093/infdis/134.supplement_1.s114. [DOI] [PubMed] [Google Scholar]
  9. Echeverria P., Siber G. R., Paisley J., Smith A. L., Smith D. H., Jaffe N., Paed D. Age-dependent dose response to gentamicin. J Pediatr. 1975 Nov;87(5):805–808. doi: 10.1016/s0022-3476(75)80316-7. [DOI] [PubMed] [Google Scholar]
  10. Federspil P., Schätzle W., Tiesler E. Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin. J Infect Dis. 1976 Aug;134 (Suppl):S200–S205. doi: 10.1093/infdis/134.supplement_1.s200. [DOI] [PubMed] [Google Scholar]
  11. Goodman E. L., Van Gelder J., Holmes R., Hull A. R., Sanford J. P. Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin. Antimicrob Agents Chemother. 1975 Oct;8(4):434–438. doi: 10.1128/aac.8.4.434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hull J. H., Sarubbi F. A., Jr Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med. 1976 Aug;85(2):183–189. doi: 10.7326/0003-4819-85-2-183. [DOI] [PubMed] [Google Scholar]
  13. Jelliffe R. W. Letter: Creatinine clearance: bedside estimate. Ann Intern Med. 1973 Oct;79(4):604–605. doi: 10.7326/0003-4819-79-4-604. [DOI] [PubMed] [Google Scholar]
  14. Kaye D., Levison M. E., Labovitz E. D. The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function. J Infect Dis. 1974 Aug;130(2):150–154. doi: 10.1093/infdis/130.2.150. [DOI] [PubMed] [Google Scholar]
  15. Klastersky J., Daneau D., Swings G., Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis. 1974 Feb;129(2):187–193. doi: 10.1093/infdis/129.2.187. [DOI] [PubMed] [Google Scholar]
  16. Lerner S. A., Seligsohn R., Matz G. J. Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin. Am J Med. 1977 Jun;62(6):919–923. doi: 10.1016/0002-9343(77)90661-1. [DOI] [PubMed] [Google Scholar]
  17. Lockwood W. R., Bower J. D. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrob Agents Chemother. 1973 Jan;3(1):125–129. doi: 10.1128/aac.3.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. McHenry M. C., Gavan T. L., Gifford R. W., Jr, Geurkink N. A., Van Ommen R. A., Town M. A., Wagner J. G. Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration. Ann Intern Med. 1971 Feb;74(2):192–197. doi: 10.7326/0003-4819-74-2-192. [DOI] [PubMed] [Google Scholar]
  19. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Regamey C., Gordon R. C., Kirby W. M. Comparative pharmacokinetics of tobramycin and gentamicin. Clin Pharmacol Ther. 1973 May-Jun;14(3):396–403. doi: 10.1002/cpt1973143396. [DOI] [PubMed] [Google Scholar]
  21. Sawchuk R. J., Zaske D. E., Cipolle R. J., Wargin W. A., Strate R. G. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther. 1977 Mar;21(3):362–369. doi: 10.1002/cpt1977213362. [DOI] [PubMed] [Google Scholar]
  22. Siersbaek-Nielsen K., Hansen J. M., Kampmann J., Kristensen M. Rapid evaluation of creatinine clearance. Lancet. 1971 May 29;1(7709):1133–1134. doi: 10.1016/s0140-6736(71)91873-3. [DOI] [PubMed] [Google Scholar]
  23. Stevens P., Young L. S., Hewitt W. L. Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med. 1975 Aug;86(2):349–359. [PubMed] [Google Scholar]
  24. Winters R. E., Litwack K. D., Hewitt W. L. Relation between dose and levels of gentamicin in blood. J Infect Dis. 1971 Dec;124 (Suppl):S90–S95. doi: 10.1093/infdis/124.supplement_1.s90. [DOI] [PubMed] [Google Scholar]
  25. Zaske D. E., Sawchuk R. J., Gerding D. N., Strate R. G. Increased dosage requirements of gentamicin in burn patients. J Trauma. 1976 Oct;16(10):824–828. doi: 10.1097/00005373-197610000-00014. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES